Clinical trials: Alzheimer Dementia
Alzheimer Disease
The Ketogenic Diet in the Treatment of Alzheimer's Disease
This research is a randomized, double-blind, placebo-parallel controlled, and multi-center clinical study in China, aiming to evaluate the tolerability, efficacy, and safety of JT821 (Ketogenic Diet) in the treatment of mild to…
- Trial name
- JT821 (NCT06681948)
- Testing
- Ketogenic diet
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Capital Medical University
Dementia
Treatment in Occupational Therapy With Significant Activities to Improve Quality of Life
We followed a pretest-posttest non-equivalent control group experimental design study comparing two cohorts of patient with different types of dementia.
- Trial name
- NCT05359978
- Testing
- To with significance activities
- Where
- Spain
- Volunteers
- 240 people
- Sponsor
- Universidad de Burgos
Alzheimer Disease, Dementia
The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia
This study aims to analyze how warning letters sent to physicians prescribing high levels of the antipsychotic quetiapine affected the health and quality of life of their patients with dementia.
- Conditions
- Alzheimer Disease, Dementia, Prescribing, Off-Label
- Trial name
- NCT05172687
- Testing
- Overprescribing letter to attributed physician
- Where
- 3 sites in United States
- Volunteers
- 336,460 people
- Sponsor
- Columbia University
Mild Cognitive Impairment
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study.
- Trial name
- NCT05015478
- Testing
- Tailored Rhythmic Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease, Mild Cognitive Impairment
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
This study will evaluate the safety, tolerability, and pharmacokinetics of MK-4334 administered once daily (QD) in participants with Alzheimer's clinical syndrome receiving a stable, daily dose of donepezil 10 mg, taken orally…
- Trial name
- NCT03740178
- Testing
- MK-4334, Donepepzil
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Late Onset
The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia
Background and objectives: The aims of this naturalistic study were: to analyze factors which could be predictive of good response to cholinesterase inhibitors (ChEI), such as: age, sex, schooling, mild (CDR 1) or moderate…
- Trial name
- NCT02187276
- Testing
- cholinesterase inhibitors
- Volunteers
- 129 people
- Sponsor
- Federal University of Minas Gerais
Alzheimer Disease
Open-Label Extension Protocol to SNK01-AD01 Study
Open-Label Extension Protocol to SNK01-AD01 Study
- Trial name
- NCT07228078
- Testing
- SNK01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NKGen Biotech, Inc.
Alzheimer Disease
University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core
This is a cross-sectional, observational study that characterizes research participants with Alzheimer's disease (AD) for their patterns of brain degeneration with the investigational tau positron emission tomography (PET)…
- Trial name
- NCT04437290
- Testing
- investigational radiotracer [18F]MK6240
- Volunteers
- 300 people
- Sponsor
- University of Washington
Alzheimer Disease
CLarifying ABCB1's Role in Alzheimer's Disease
Alzheimer's disease is biologically defined by the accumulation of amyloid beta and tau protein, identified using cerebrospinal fluid biomarkers.
- Trial name
- CLeAR-AD (NCT07393113)
- Testing
- ABCB1 genotyping
- Where
- France
- Volunteers
- 510 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD.
- Trial name
- NCT04740580
- Testing
- Glycine, N-acetylcysteine, Alanine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Baylor College of Medicine
Alzheimer Disease, Dementia
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05527288
- Testing
- Drug: [18F]florbetaben
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease
A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures.
- Trial name
- NCT00165659
- Testing
- DONEPEZIL HYDROCHLORIDE
- Where
- 65 sites in Japan
- Sponsor
- Eisai Limited
Pregnancy Related
TeamBaby - Safe, Digitally Supported Communication in Obstetrics and Gynecology
The purpose of this project with obstetric healthcare workers, pregnant women and their relatives is to improve communication between all parties involved in order to increase sustainable patient safety.
- Trial name
- TeamBaby (NCT03855735)
- Testing
- TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)
- Where
- 2 sites in Germany
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Jacobs University Bremen gGmbH
Nonverbal Communication, Critical Illness
Vidatalk Communication Application: Usability, Acceptability and Efficacy Study
This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium…
- Trial name
- NCT02921776
- Testing
- Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Ohio State University
Alzheimer Dementia, Agitation,Psychomotor
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia…
- Trial name
- ECT-AD (NCT03926520)
- Testing
- Electroconvulsive Therapy (ECT)
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Brent Forester
Alzheimer Disease
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their…
- Trial name
- HEAD (NCT05361382)
- Testing
- 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 822 people, healthy volunteers welcome
- Sponsor
- Tharick Pascoal
Diet, Polyphenols, Flavonoids, Stilbenes, Aged, Dementia, Alzheimer's Disease, Epidemiology
Polyphenols and Risk of Dementia
This project aims to leverage existing data from a large observational prospective study on dementia, the Three-City study, to investigate the relationship between intakes of polyphenols and the risk to develop dementia in the 12…
- Trial name
- NCT03286608
- Testing
- observational study (no intervention)
- Volunteers
- 1,329 people, healthy volunteers welcome
- Sponsor
- Jean-François Dartigues
Alzheimer Disease
The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease
The purpose of this study is to examine whether the rTMS (repetitive Transcranial Magnetic Stimulation) could change cortical excitability measured by off-line EEG in Alzheimer's Disease (AD) patients.
- Trial name
- NCT01970150
- Testing
- rTMS real
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer's Disease
Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)
Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown.
- Trial name
- NCT00987090
- Testing
- Clinic and neuropsychologic evaluation, MRI, PET
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Alzheimer Disease, Smell Loss
Olfactory Biopsies
This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell.
- Conditions
- Alzheimer Disease, Smell Loss, Smell Dysfunction
- Trial name
- NCT07021040
- Testing
- olfactory testing, Odor stimulation, Olfactory biopsy
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.